AIM ImmunoTech Stock Gains Over Final Approval Of Novel Cancer Therapy Patent In Japan

Shares of AIM ImmunoTech (AIM) surged about 80% after the Japan Patent Office approved a Japanese patent covering the use of Ampligen (rintatolimod) in combination with checkpoint inhibitors. The approval strengthens AIM's IP position in Japan and could improve commercialization or partnering prospects for Ampligen in that market. The stock reaction appears sharp and speculative, reflecting investor revaluation of the company's prospects following the patent news.

Analysis

Shares of AIM ImmunoTech (AIM) surged about 80% after the Japan Patent Office approved a Japanese patent covering the use of Ampligen (rintatolimod) in combination with checkpoint inhibitors. The approval strengthens AIM's IP position in Japan and could improve commercialization or partnering prospects for Ampligen in that market. The stock reaction appears sharp and speculative, reflecting investor revaluation of the company's prospects following the patent news.